Glucose abnormalities in schizophrenia, bipolar and major depressive disorders

Modern Trends in Pharmacopsychiatry

Volumn 26, Issue , 2009, Pages 47-65

  Bushe, Chris ^a  

^a Lilly UK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; SOMATOMEDIN C; ZIPRASIDONE;

BIPOLAR DISORDER; DIABETIC PATIENT; DRUG USE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEALTH PROGRAM; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR DEPRESSION; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION;

EID: 67649935709     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000189774     Document Type: Review

References (97)

1. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophr Res 2008; 101:273-278.
2. Diabetes Atlas©, ed 3. International Diabetes Federation, 2006. (At /www.eatlas.idf.org/ accessed 1 March 2008.)
3. www.bhf.org
4. www.unitefordiabetes.org (accessed 1 March 2008).
5. Centers for Disease Control and Prevention. www.cdc.gov/nchs/about/major/ nhis/released200303.htm
6. Kohen D: Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004;47:S64-S66.
7. Dixon L, Weiden P, Delahanty J: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;2:903-912.
8. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
9. Bushe C, Holt R: Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004;47:S67-S71.
10. Subramaniam M, Chong SA, Pek E: Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48:345-347.
11. Taylor D, Young C, Esop R, Paton C, Walwyn R: Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185:152-156.
12. Taylor D, Young C, Mohamed R, Paton C, Walwyn R: Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19: 182-186.
13. Citrome L, Jaffe A, Levine J, Allingham B, Robinson: Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-1013.
14. Flegal KM, Carroll MD, Ogden CL, et al: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727.
15. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A: Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 2005;8:183-194.
16. Citrome L, Jaffe A, Levine J, et al: Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr Serv 2006; 57:1132-1139.
17. National Center for Chronic Disease Prevention and Health Promotion. Incidence of diabetes. 2005 //www.cdc.gov/diabetes
18. van Winkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A, Peuskens J: Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472-479.
19. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006;67:1493-1500.
20. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K: Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 2006;164:672-681.
21. Leslie DL, Rosenheck RA: Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-1711.
22. Miller EA, Leslie DL, Rosenheck RA: Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193:387-395.
23. Lambert MT, Copeland LA, Sampson N, Duffy SA: New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:919-923.
24. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J: Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health 2006;2:14.
25. Expert Group: 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003:consensus summary. Br J Psychiatry 2004;184(suppl 47):S112-S114.
26. Expert Group: Metabolic and lifestyle issues and severe mental illness - new connections to well-being? Expert consensus meeting Dublin 2005. J Psychopharm 2005;19(6 suppl):118-122.
27. Gough S, Peveler R: Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatry Suppl 2004;47:S106-S111.
28. Sernyak MJ, Gulanski B, Rosenheck R: Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005; 66:1463-1467.
29. Ryan MC, Collins P, Thakore JH: Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160:284-289.
30. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE Bipolar Guidelines, 2006. www.nice.org.uk (accessed 9 March 2008).
31. Cassidy F, Ahearn E, Carroll BJ: Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417-1420.
32. Regenold WT, Thapar RK, Marano C, et al: Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19-26.
33. Yumru M, Savas HA, Kurt E, Kaya MC, Selek S, Savas E, Oral ET, Atagun I: Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007;98:247-252.
34. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ: Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-430.
35. Goethe JW, Szarek BL, Caley CF, Woolley SB: Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 2007;68:22-28.
36. Willis T: Diabetes: A Medical Odyssey. New York, Tuckahoe, 1971.
37. Lustman PJ, Clouse RE: Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Compl 2005;19:113-122.
38. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069-1078.
39. Lustman PJ, Clouse RE, Freedland KE: Management of major depression in adults with diabetes: implications of recent clinical trials. Semin Clin Neuropsychiatry 1998;3:102-114.
40. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE: Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:934-942.
41. Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, SOHO Study Group: Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17:235-244.
42. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R: Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002;26:137-141.
43. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH: The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 20045;74:1999-2008. Erratum in: Life Sci 2004;75:2851.
44. Ader M, Garvey WT, Phillips LS, Nemeroff CB, Gharabawi G, Mahmoud R, Greenspan A, Berry SA, Musselman DL, Morein J, Zhu Y, Mao L, Bergman RN: Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res 2008;42:1076-1085.
45. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, Joukhadar C, Müller M, Kasper S: Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 2008;33: 1633-1641.
46. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC: Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28.
47. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC: Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006;67:789-797.
48. McEvoy J, Meyer M, Goff D, Nasrallah H, Davis S, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.
49. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, Beasley CM Jr, Dananberg J: Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87:2918-2923.
50. Haupt DW, Fahnestock PA, Flavin KA, Schweiger JA, Stevens A, Hessler MJ, Maeda J, Yingling M, Newcomer JW: Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology 2007;32:2561-2569.
51. Chiu CC, Chen KP, Liu HC, Lu ML: The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol 2006;26:504-507.
52. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-871.
53. Hardy TA, Meyers AL, Yu J, Shankar SS, Steinberg HO, Porksen NK: Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks. Diabetes Care 2007;30:157-158.
54. Wu MK, Huang CY, Liou YJ, Wang CK, Lee SD: Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obes (Lond) 2008;32:436-442.
55. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B: Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 2008;98:302-306.
56. Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;i:495.
57. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN: Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007;191:23-29.
58. Valdez R, Yoon PW, Liu T, Khoury MJ: Family history and prevalence of diabetes in the U.S. population: the 6-year results from the National Health and Nutrition Examination Survey (1999-2004). Diabetes Care 2007;30:2517-2522.
59. Mata-Cases M, Fernández-Bertolín E, Cos-Claramunt X, García-Durán M, Mateu-Gelabert T, Pareja-Rossell C, Pujol-Ribera E: Incidence of type 2 diabetes and its diagnosis process in the decade 1991-2000 in a primary health care centre. Gac Sanit 2006;20:124-131.
60. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH: Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia. Diabet Med 2007;24: 481-485.
61. Gough SC, O'donovan MC: Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005;19(suppl):47-55.
62. Ellingrod VL, Miller del D, Taylor SF, Moline J, Holman T, Kerr J: Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008;98:47-54.
63. Holt RI, Bushe C, Citrome L: Diabetes and schizophrenia 2005:are we any closer to understanding the link? J Psychopharmacol 2005;19(suppl):56-65.
64. Graham KA, Cho H, Brownley KA, Harp JB: Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008;101:287-294.
65. Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L: Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 2004;65:1335-1342.
66. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP: Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184: 58-62.
67. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, Shetty KT: Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164:1557-1560.
68. Gunnell D, Holly JM: Hypothesis: do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia? Schizophr Res 2004;71:191-193.
69. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 596-601.
70. Barnett AH, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A, Hill J, Millar H, Peveler R, Rees A, Singh V, Taylor D, Vora J, Jones P: Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007;21:357-373.
71. Koro CE, Fedder DO, L'Italien GJ, et al: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case control study. Br Med J 2002;325:243-248.
72. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J: Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007;298:2654-2664.
73. McCreadie RG, Scottish Schizophrenia Lifestyle Group: Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003;183:534-539.
74. Bushe C, Haddad P, Peveler R, Pendlebury J: The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005;19(suppl):28-35.
75. Smith S, Yeomans D, Bushe CJ, Eriksson C, Harrison T, Holmes R, Mynors-Wallis L, Oatway H, Sullivan G: A well-being programme in severe mental illness: baseline findings in a UK cohort. Int J Clin Pract 2007;61:1971-1978.
76. Smith S, Yeomans D, Bushe CJ, Eriksson C, Harrison T, Holmes R, Mynors-Wallis L, Oatway H, Sullivan G: A well-being programme in severe mental illness. Reducing risk for physical ill-health: a post-programme service evaluation at 2 years. Eur Psychiatry 2007;22:413-418.
77. Bushe CJ, Leonard BE: Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68:1682-1690.
78. Bushe C, Leonard B: Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry Suppl 2004;47:S87-S93.
79. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA: Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296.
80. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
81. Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R, Clozapine and Risperidone Enhancement (CARE) Study Group: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
82. Olanzapine USA Label 2008.
83. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of early psychosis: a randomised, double blind 52 week comparison. Am J Psychiatry 2007;164:1050-1060.
84. Haddad PM: Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry Suppl 2004;47:S80-S86.
85. Citrome LL, Holt RI, Zachry WM, Clewell JD, Orth PA, Karagianis JL, Hoffmann VP: Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41:1593-1603.
86. Rettenbacher MA, Hummer M, Hofer A, Baumgartner S, Ebenbichler C, Edlinger M, Kemmler G, Lechleitner M, Wolfgang Fleischhacker W: Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol 2007;21:400-404.
87. Taylor D, Paton C, Kerwin R: The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, ed 9. Informa Healthcare 2007.
88. Haddad P, Dursun SM: Selecting antipsychotics in schizophrenia: lessons from CATIE. J Psycho pharmacol 2006;20:332-334.
89. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C: Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22: 363-370.
90. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC: Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-1121.
91. Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, Tsunoda K, Nio S, Den R, Manki H, Tanabe A, Yagi G, Kashima H: How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) 2007;195:285-295.
92. Paton C, Esop R, Young C, Taylor D: Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305.
93. www.idf.org: Guideline for management of post-meal glucose 2007 (accessed 25 Feb 2008).
94. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI: Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007;115:286-294.
95. Lee SJ, Choi EJ, Kwon JS: A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2008;69:555-562.
96. Mauri M, Simoncini M, Castrogiovanni S, Iovieno N, Cecconi D, Dell'Agnello G, Quadrigli M, Rossi A, Donda P, Fagiolini A, Cassano GB: A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry 2008;41:17-23.
97. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M: Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004;65:471-477.